A trial of Pfizer Inc’s experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday. The results appear to surpass those seen with Merck & Co Inc’s pill, molnupiravir, which was … Continue reading Pfizer says antiviral pill cuts risk of severe COVID-19 by 89%